1. AB0412 Exploratory Results from The Bliss and Illuminate Trials Support The Design of The CHABLIS-SC1 Trial, A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study To Evaluate The Efficacy and Safety of Blisibimod Administration in Subjects with Systemic Lupus Erythematosus. (15th July 2016) Authors: Merrill, J.T.; Strand, V.; Hislop, C.; Gangal, M.; Martin, R.S.; Kalunian, K.C. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 1047 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Characterization of the Etna volcanic emissions through an active biomonitoring technique (moss-bags): Part 1 – Major and trace element composition. (January 2015) Authors: Calabrese, S.; D'Alessandro, W.; Bellomo, S.; Brusca, L.; Martin, R.S.; Saiano, F.; Parello, F. Journal: Chemosphere Issue: Volume 119(2015) Page Start: 1447 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Characterization of the Etna volcanic emissions through an active biomonitoring technique (moss-bags): Part 1 – Major and trace element composition. (January 2015) Authors: Calabrese, S.; D'Alessandro, W.; Bellomo, S.; Brusca, L.; Martin, R.S.; Saiano, F.; Parello, F. Journal: Chemosphere Issue: Volume 119(2015) Page Start: 1447 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. FRI0388 Effects of Blisibimod on Serum Immunoglobulins and Infection Risk in Patients with Systemic Lupus Erythematosus from the Placebo-Controlled PEARL-SC and Open-Label Extension Studies. (10th June 2014) Authors: Richard, F.A.; Scheinberg, M.A.; Thomas, M.; Chu, A.D.; Martin, R.S.; Hislop, C.; Petri, M. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 527 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. FRI0389 Effects of Chronic Treatment with Subcutaneous Blisibimod on Renal and Inflammation Biomarkers in Subjects with Systemic Lupus Erythematosus in Phase 2 PEARL-SC and Open-Label Extension Studies. (10th June 2014) Authors: Richard, F.A.; Scheinberg, M.A.; Thomas, M.; Chu, A.D.; Hislop, C.; Martin, R.S.; Petri, M. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 528 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. THU0387 Effects of Blisibimod, An Inhibitor of B Cell Activating Factor, On Patient Reported Outcomes and Disease Activity in Patients with Systemic Lupus Erythematosus. (9th June 2015) Authors: Petri, M.; Martin, R.S.; Hislop, C.; Scheinberg, M.A.; Furie, R.A. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 336 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗